Maryland State Retirement & Pension System Grows Position in AbbVie Inc. $ABBV

Maryland State Retirement & Pension System increased its holdings in AbbVie Inc. (NYSE:ABBV) by 2.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 88,302 shares of the company’s stock after buying an additional 2,345 shares during the period. Maryland State Retirement & Pension System’s holdings in AbbVie were worth $20,445,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Emerald Advisors LLC grew its holdings in AbbVie by 7.2% in the third quarter. Emerald Advisors LLC now owns 6,361 shares of the company’s stock worth $1,473,000 after purchasing an additional 426 shares during the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of AbbVie by 5.6% during the third quarter. Sequoia Financial Advisors LLC now owns 84,494 shares of the company’s stock valued at $19,564,000 after buying an additional 4,485 shares during the last quarter. Hartline Investment Corp grew its stake in AbbVie by 25.1% during the 3rd quarter. Hartline Investment Corp now owns 12,288 shares of the company’s stock valued at $2,845,000 after purchasing an additional 2,462 shares during the last quarter. Financial Management Network Inc. lifted its holdings in shares of AbbVie by 50.2% during the third quarter. Financial Management Network Inc. now owns 3,627 shares of the company’s stock worth $835,000 after purchasing an additional 1,212 shares during the period. Finally, Occidental Asset Management LLC lifted its position in AbbVie by 18.4% during the third quarter. Occidental Asset Management LLC now owns 9,544 shares of the company’s stock valued at $2,210,000 after purchasing an additional 1,485 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Down 1.1%

Shares of NYSE ABBV opened at $214.38 on Friday. The business has a 50-day moving average price of $226.80 and a two-hundred day moving average price of $216.47. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The firm has a market capitalization of $378.89 billion, a PE ratio of 162.41, a PEG ratio of 0.88 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 524.24%.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

Wall Street Analysts Forecast Growth

ABBV has been the topic of several research analyst reports. Evercore ISI lifted their target price on shares of AbbVie from $207.00 to $222.00 and gave the company an “outperform” rating in a research report on Monday, September 22nd. Erste Group Bank cut AbbVie from a “buy” rating to a “hold” rating in a report on Tuesday, October 14th. Morgan Stanley boosted their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Bank of America raised their target price on AbbVie from $220.00 to $251.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, Guggenheim boosted their target price on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Three analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and a consensus price target of $247.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.